Protein-Protein Interactions as a Strategy towards Protein-Specific Drug Design: The Example of Ataxin-1

Cesira de Chiara1, Rajesh P. Menon1, Geoff Kelly2, Annalisa Pastore1*

1 National Institute for Medical Research of the Medical Research Council, London, United Kingdom, 2 Medical Research Council Biomedical NMR Centre, London, United Kingdom

Abstract

A main challenge for structural biologists is to understand the mechanisms that discriminate between molecular interactions and determine function. Here, we show how partner recognition of the AXH domain of the transcriptional co-regulator ataxin-1 is fine-tuned by a subtle balance between self- and hetero-associations. Ataxin-1 is the protein responsible for the hereditary spinocerebellar ataxia type 1, a disease linked to protein aggregation and transcriptional dysregulation. Expansion of a polyglutamine tract is essential for ataxin-1 aggregation, but the sequence-wise distant AXH domain plays an important aggravating role in the process. The AXH domain is also a key element for non-aberrant function as it intervenes in interactions with multiple protein partners. Previous data have shown that AXH is dimeric in solution and forms a dimer of dimers when crystallized. By solving the structure of a complex of AXH with a peptide from the interacting transcriptional repressor CIC, we show that the dimer interface of AXH is displaced by the new interaction and that, when blocked by the CIC peptide AXH aggregation and misfolding are impaired. This is a unique example in which palindromic self- and hetero-interactions within a sequence with chameleon properties discriminate the partner. We propose a drug design strategy for the treatment of SCA1 that is based on the information gained from the AXH/CIC complex.

Introduction

Ataxin-1 (ATX1) is the protein responsible for the currently incurable spinocerebellar ataxia type 1 (SCA1), a dominant neurodegenerative misfolding disease characterised by ataxia, progressive motor deterioration [1,2] and degeneration of selected neuronal subtypes [3]. ATX1 is part of a larger family of diseases that includes Huntingtin and other spinocerebellar ataxias. They are all believed to be caused by expansion of a polymorphic CAG repeat tract in the coding region of the respective genes [1]. However, for an increasing number of the polyQ diseases it has been shown that regions outside the polyQ tract profoundly modify and independently contribute to protein aggregation [4,5,6,7,8,9].

The pathogenic mechanism of SCA1 seems particularly complex. PolyQ expansion above a threshold of ~39 repeats is essential for disease development as shown by the linear correlation between the length of the longer uninterrupted polyQ tract and the age at onset [1]. However, overexpression of non-expanded ATX1 (30Q) in flies and mice causes phenotypes similar to those caused by overexpression of drosophila ATX1 which lacks the polyQ tract but different from those observed for polyQ peptides [10,11] strongly suggesting the presence of at least a second aggregation hotspot. This has been identified in the AXH domain (SMART SM00536) [12], a motif responsible for transcriptional repression and RNA-binding activity of ATX1 [5,11,13,14,15,16,17,18]. The AXH domain is also necessary and sufficient for the majority of the known ATX1 interactions with other proteins, most of which are transcriptional regulators (SMRT, Gfi-1, CIC, Sp1 and Tip60) [11,13,14,15,16].

Although AXH does not contain a polyQ tract and is sequence-wise distant from it, independent evidence indicates an important role of AXH in ATX1 aggregation. We have recently demonstrated that the AXH domain has an unusual chameleon oligonucleotide-binding (OB) fold, a structural motif involved in nucleic acid and protein recognition [19]. In solution, the isolated AXH forms a complex equilibrium between monomer, dimer, tetramer and higher molecular weight species that are on-pathway to protein misfolding and fiber formation [20]. The presence of the AXH domain favours formation of intra-nuclear aggregates of expanded ATX1 in eukaryotic cells [5]. The evidence of an involvement of AXH as an independent aggregation hotspot is so compelling that Zoghbi and coworkers went as far as suggesting that ‘the AXH domain but not the expanded polyQ tract is necessary to generate the ATX1 gain-of-function phenotype in flies or mice’ [11].

In our quest for a treatment of SCA1, we reasoned that protein-protein interactions could be the basis of a strategy to prevent ATX1 aggregation in a specific and effective way. This concept is supported by several examples which indicate protein-protein interaction as one of the way proteins protect themselves from aberrant aggregation [21]. If we could exploit this concept, we might be able to obtain protecting molecules that engage in specific interactions with the protein of interest providing an
approach different from the use of small compounds such as
dihydropyridines and phenols [22]. Although somewhat effective in vitro,
these compounds are typically non-specific and tend to act on
more than one pathway in vitro.

With this aim in mind, we considered the interaction between
the AXH domain and a linear motif of the CIC protein, the
human orthologue of the Drosophila transcriptional repressor
capicua. CIC is an HMG-box protein that forms a stable
interaction both with wild-type and expanded ATX1 and
participates in the formation of large native complexes in mouse
cerebellum [23]. CIC is the only one of the ATX1 binding
partners whose expression levels are significantly reduced in
ATX1-null mice [14] and whose structure in a complex with
ATX1 is known [24]. Reduction of the CIC levels correlates with
mitigation of the SCA1 disease phenotypes [25]. It was recently
shown that a peptide 28 amino acids-long spanning the N-
terminus of CIC competes dimer formation of AXH but in turn
causes CIC mediated dimerisation [24].

Here, we show how a ten residues peptide is the region
necessary and sufficient to bind to ATX1 AXH in solution and
out-compete dimerisation and further aggregation by stabilizing
the AXH monomer. Recognition occurs with high affinity but low
sequence specificity, suggesting that the mechanism is not just
restricted to CIC but is a more general mode of interaction of
ATX1 with protein partners. The structure of the complex
describes, at a molecular level, the mechanism by which ATX1
exerts its transcription co-repressor function and constitutes a
novel example of a conformational switch. Our results provide the
basis for the development of a new strategy for the specific
treatment of SCA1 based on peptide mimetics of the CIC peptide.

Results

Defining the Sequence of the CIC Linear Motif
Recognized by AXH

We first checked the minimal length of CIC that would retain a
high affinity interaction without causing further CIC-mediated
dimerisation. We thus designed the peptide by selecting the region
conserved among species (WHSLVPFL, (Figure 1A). Flanking
residues from the natural sequence were added at the N- and C-
termini (one and four residues respectively) to increase solubility
(CICp). Isothermal titration calorimetry (ITC) measurements
showed that the AXH domain interacts with CICp with a
dissociation constant (Kd) of 8 \mu M. The addition of only two
amino acids, V34 and F35, at the N-terminus (L-CICp) signifi-
cantly increases the peptide affinity as the Kd decreases by
two orders of magnitude (\sim 33 nM) (Figure 1B). Interestingly, the
two additional amino acids are fully conserved throughout
vertebrates, but not in D. melanogaster, even though interaction
between CIC and ATX1 orthologues has also been described in
these organisms [14]. Further N-terminal extension to include up
to four additional amino acids resulted in a peptide with a Kd
comparable to that of L-CICp (\sim 24 nM).

To assess the specific contribution of each amino acid in the
peptide, we individually mutated to alanines the residues from V34
to P46 with the exception of A45, which was mutated to a glycine.
Only mutation of residues W37 and L40 affects binding with a
decrease of the Kd of 100- and 10-fold respectively, whereas all the
other mutations did not significantly influence the affinity
(Figure 1C).

These results confirm and quantify the affinity of the interaction
at the amino acid level. They also show that the presence rather
than the specific individual nature of extra N-terminal amino acids
is important to stabilize the complex.

Figure 1. Interaction of the CIC peptides with ATX1 AXH. A) Sequence alignment of CIC sequences from different species. Numbering of CIC is according to UniProtKB/Swiss-Prot Q96R0K. The ATX1 interacting motif spanned by L-CICp sequence is also present in the Capicua-like protein/double homeodomain 4 fusion protein (CIC/DUX4 fusion) involved in the up-regulation of PEAM3 family genes in Ewing-like sarcomas [48]. B) ITC profile for the binding of ATX1 AXH to L-CICp. Row calorimetric data (upper plot) and resulting integrated enthalpy data fit to a single-site binding model (lower plot). C) Dissociation constants (\mu M) of ATX1 AXH to wild-type and mutant L-CICp peptides where each position was individually mutated to alanine with the exception of A45 which was mutated to glycine. For comparison, the Kd of wild-type AXH with L-CICp is 0.03 \mu M.
doi:10.1371/journal.pone.0076456.g001

The AXH Domain Binds the CIC Linear Motif as a
Monomer

The [15N1H]-HSQC spectrum of the isolated ATX1 AXH
contains more resonances than expected on the basis of the sequence
with the peak intensities being highly heterogeneous (Figure 2A, top). Using a combination of NMR, analytical
ultracentrifugation, X-ray and small angle scattering, we have
previously shown that the observed behaviour is consistent with the
presence of a monomer-dimer-tetramer equilibrium over a
wide range of concentrations as well as with conformational heterogeneity of the different protomers [20]. When we titrated the
15N-labelled AXH with unlabelled L-CICp, the NMR
spectrum underwent a dramatic change (Figure 2A, bottom).
The spectrum of AXH fully saturated with L-CICp (at a ca. 2:1 L-
CICp:AXH molar ratio) is indicative of the presence of a single

PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e76456
species (i.e. a monomer or a symmetric multimer) as it contains the expected total number of resonances. The NMR relaxation parameters reveal well the state of aggregation of the domain. At the same field (600 MHz) and temperature (27°C), we observe a drop of the average $T_1$ values from 1s to 700 ms and an increase of the average $T_2$ values from 70 ms to 80 ms ([Figure 2B], to be compared with values previously published for the isolated AXH [26]). From these parameters, we estimated a correlation time ($\tau_c$) of 6.5 ns for the complex, a value consistent with a monomeric species of the molecular weight of AXH. This value should be compared to the $\tau_c$ of 12 ns obtained for the AXH dimer before addition of the peptide. This evidence was further confirmed by size exclusion chromatography measurements ([Figure 2C]): while isolated AXH elutes around 12.5 mL, which is close to the carbonic anhydrase standard (29 kDa), the complex elutes at a volume compatible with a 15.5 kDa species, which is approximately the size of the AXH monomer bound to L-CICp.

These results indicate that interaction with the peptide outcompetes dimer formation by affecting directly or indirectly the dimer interface and leads to a complex of the monomeric AXH with CIC.

**L-CICp forms a Tight Complex with AXH**

To gain more insights into the recognition of ATX1 by CIC in solution that could then be compared with the crystal structure of a complex with a longer CIC peptide [24], we solved the structure of the complex of the AXH domain with L-CICp based on intran-
and inter-molecular distance restraints. The bundle of solutions is well defined, with the energetically best 15 structures superimposing with a root mean square deviation (r.m.s.d.) of 0.63±0.14 Å on backbone atoms of the structured regions (L-CICp 34–44, AXH 575–689) (Figure 3A, B and Table S1). The peptide conformation and its interaction with the domain rely on 144 restraints, 100 of which being unambiguous.

The peptide binds in an extended conformation. Overall the backbone and side-chains of L-CICp from V34 to L44 are well defined. The r.m.s.d steadily increases from A45 to Q48 as compared to the preceding residues, thus indicating that the last four amino acids experience significantly higher flexibility and/or conformational disorder. This agrees with the observation that compared to the preceding residues, thus indicating that the last defined. The r.m.s.d steadily increases from A45 to Q48 as

Figure 3. Solution structure of the ATX1 AXH/L-CICp complex. A) Structure bundle of the lowest energy 15 structures of the complex superimposed on residues 575–689 of the AXH domain. The backbone of the domain is shown in blue, L-CICp in red. B) Ribbon representation of AXH with the peptide shown in a full heavy atom representation. The N- and C-termini are marked. The peptide sequence is indicated at the bottom together with the direction N-to-C indicated by an arrow. C) The same as in B) but showing the peptide as a ribbon. The backbone atoms of V34 and F35 pair with residues of the domain and form an additional short β-sheet (highlighted with a yellow circle). D) Details of the most important interactions of the peptide with the domain. The side chains of AXH residues that form extensive interactions with L-CICp W37 and L40 are shown explicitly.

doi:10.1371/journal.pone.0076456.g003

that is important for the formation of this extra stabilizing structural element.

Besides these contacts, the L-CICp side-chains form extensive contacts with conserved residues of the AXH core: V34 (I580, L588), F35 (P573), W37 (F599, S602, L609, L686), L40 (I581, V591, L594), V41 (L686) and L44 (V641, V643). Most of the interactions between the protein and the peptide are mediated by the main- and side-chain of W37 and by the L40 and L44 side-chains (Figure 3D), as directly supported by intermolecular NOEs derived from NMR filtered experiments. The structure explains why W37 plays a major role in determining the high affinity between the peptide and the AXH domain: the W37 side chain inserts itself into a groove formed by A584 of the turn between β1 and β2, S602 of helix1, L609 of β3 and L686 of β9. ITC analysis of the alanine mutants shows that among the remaining conserved large hydrophobic residues of the peptide that orient their chains towards the core of the domain (i.e. L40, L44 and V45), only L40, besides W37, appreciably decreases the affinity when singly mutated into alanine. Indeed, the side-chain of L40 is inserted into a pocket of the AXH core even more deeply than W37, and occupies a cavity defined by I581 of β1, V591 and L594, F599 of helix1, and F652, W658 and L672 of β6, β7 and N-terminus of β8, respectively. It is only apparently surprising that most of the other mutants, particularly the ones like L44 and V45 which orient their side-chains into AXH hydrophobic pockets, bind with Kds comparable to wild-type L-CICp. This observation supports the ‘plasticity’ of the AXH domain as exemplified by the mutual adaptation of the two structurally different N-termini of the protomers in the dimer [27]. The alanine scan thus indicates that small structural adjustments are allowed, and must be occurring, in the AXH core in order to adapt structurally and allow accommodation of an alanine in a pocket where bulkier side-chains, like L44 and V45, have evolved to bind, without this quantitatively affecting the global affinity of the peptide. Further data using double and/or multiple mutants of the peptide, also with amino acids other than alanine, will be required to test the limits of this model and gain more information on amino acids which could be allowed or disallowed in key positions of the L-CICp sequence. Confirmation of the generous structure adaptability of the domain comes also from mutations tested on the protein side [24]. The authors could detect a decrease in the affinity between AXH and peptide CICp only with combined mutations of highly conserved residues, in pairs or with a triple mutant, whereas single mutations showed affinity comparable to the wild-type [24].

Combining the analysis of the solution structure with our ITC results on the shorter CICp peptide we can thus argue that the stretch P36 to L44 represents the minimal region of CIC that is necessary and sufficient to disrupt AXH homodimerization and form a monomeric complex.

L-CICp Binds to the AXH Surface Involved in Dimerisation of the Domain

Comparison between the AXH dimer and the CIC complex reveals interesting features. The fold of the AXH monomer in the complex is similar to that of the individual protomers in the free ATX1 AXH (Figure 4A). The average structure, as calculated by Wheatsheaf [28], shows average r.m.s.d. values of 1.9±0.4 Å and 2.5±0.4 Å respectively for the backbone and heavy atoms of residues 575–688 when superimposed to chains A, C and D of the crystal structure 1OA8 [27]. The more divergent chain B superposes similarly well when excluding the loop between residues 396–610 due to the extensive unfolding of helix 1. In the individual dimers, the protomers pack against each other as

The same as in B) but showing the peptide as a ribbon. The backbone atoms of V34 and F35 pair with residues of the domain and form an additional short β-sheet (highlighted with a yellow circle). D) Details of the most important interactions of the peptide with the domain. The side chains of AXH residues that form extensive interactions with L-CICp W37 and L40 are shown explicitly.
two right hand palms that touch each other in an antiparallel fashion so that the two thumbs are close in space and parallel. Accordingly, the first seven N-terminal amino acids (A567–P573, corresponding to the thumbs) of each monomer pack against the core of the other protomer (the palm of the other hand) and are extensively involved in defining the dimer interface (Figure 1A).

In the complex, the peptide replaces, in a reversed orientation, the N-terminus of the other dimer protomer, having a similar effect in shielding the hydrophobic core of the AXH domain from solvent exposure (compare Figure 3B and 4B). The peptide pushes out the N-terminal residues of the domain (A567–P573) which, in the complex, are unstructured and flexible and do not make contacts with the rest of the domain or with the bound peptide. In our hands metaphor, they are like a thumb in a fully open hand. What is particularly interesting is that L-CICp does not simply replace the dimer interface but completely remodels it (Figure 4C). In the dimer, the cavity in the concave region of the approximately sickle-cell-like shape of the AXH monomer accommodates the N-termini of both protomers in a parallel orientation. The peptide replaces both termini and gains a completely different arrangement mediated by the side-chains of W37 and L40. These bulky hydrophobic interactions are absent in the N-terminus sequence, which is dominated by prolines. Likewise, despite sharing the same cavity, the backbone conformations of the peptide in the complex and of the N-termini in the dimer are quite different as are also the contacts between the side-chains with the surroundings, suggesting very distinct structural solutions.

An unusually strong adaptability of the AXH domain to the specific partner is also highlighted by the asymmetry that the protomer structures have in the dimers, especially at the N-termini, which adopt different conformations in each protomer (Figure 4D).

These results indicate a direct competition between protein-protein interactions and self-association of ATX1 AXH and confirm the importance of the extraordinary structural plasticity of the domain in setting up the rules for protein-protein recognition.

Partner recognition plays an essential role in determining the state of aggregation of ATX1.

Interaction with L-CIC Stabilizes the AXH Monomer and Prevents Aggregation

We had previously demonstrated that the AXH has an intrinsic tendency to aggregate and form fibers in vitro and is able to modulate the aggregation of the full-length expanded ATX1 in vivo [5,29]. We wondered whether, given its properties, L-CIC could also out-compete aggregation and misfolding of the AXH domain. We tested in parallel two different constructs of the AXH domain, one spanning residues (AXH568–694) used in the previous characterization [5,29] and a second C-terminally shorter construct (AXH567–689) used for structure determination of the L-CICp complex. Both constructs were incubated at 37°C (assumed as a reference for the physiological temperature) in the absence and presence of L-CICp (in 3 equivalent molar excesses to AXH). Aggregation was monitored over time by analytical size-exclusion chromatography. Both constructs aggregated in their free forms resulting in a decrease of the initial peak of the ‘monodispersed’ species and the appearance over time of a second species which ran with the void volume of the Sephadex 75 column (MW ≥100 kDa) (Figure 5). AXH568–694 showed faster kinetic than AXH567–689: after 8 days of incubation, AXH568–694 was 100% aggregated, whereas the AXH567–689 sample still showed ~60% of the initial species after 14 days. This observation is in line with what previously observed, i.e. that C-terminal elongation accelerates aggregation [18]. For both constructs, complex formation with L-CICp completely hampers aggregation: AXH568–694/L-CICp complex remains unchanged after 30 days at 37°C.

These results clearly demonstrate that interaction with the peptide is effective in stabilizing the monomeric species and preventing aggregation of the domain.

Discussion

Protein-protein interactions play an essential role in determining the localization, functions and fate of proteins in the living cell. A main challenge for Structural Biology is to understand the rules that control interaction specificity, a topic of particular importance, for instance, in interpreting how proteins discriminate between functional interactions and self-assembly and aggregation. The complexity of this task arises not only from the number of proteins expressed by the organism (which, taking into account alternative splicing or post-translational modifications, is much higher than the number of coding genes), but also from the combinatorial cross-talk between them [30,31,32]. Here, we have
Our data have important implications for understanding both normal and pathologic functions of ATX1.

AXH is an important functional domain of ATX1 already known to participate in vivo in protein-protein interactions with other partners [34]. The involvement of ATX1 in transcriptional regulation was originally inferred from the identification of several transcriptional co-regulators as modulators of the ATX1-mediated eye phenotype in Drosophila [10]. Thereafter, a number of different factors involved in transcription were discovered to interact directly with ATX1 [11,13,14,15,16,35,36]. The isolated AXH domain itself was found to repress transcription when tethered to DNA [5], similarly to the full-length protein [37]. However, no direct cross-linking of AXH to DNA was detected, suggesting that the interaction with other DNA-binding proteins could be required [5]. One of such proteins is CIC which was shown to require the AXH domain for interaction [11,13,14,15,16]. The structure of the CIC/AXH complex provides the structural determinants of the recognition between these proteins and a mechanistic model of how ATX1 could act synergistically with CIC to regulate transcription.

Figure 6. Unique pseudo-barrel of AXH uses its concave side to recognize CIC, leaving available the putative RNA-binding surface for further functional interactions [27,38]. It could be speculated that the two structural states might be related to different functional aspects of the protein, which has been proposed to play a dual role in regulation of transcription and RNA-processing and/or metabolism [23,39,40]. The same recognition code could also be adopted with other ATX1 partners. Our data show in fact that, despite the high affinity, only W37 and L40 provide a significant contribution to specificity. The low homology between L-CICp and the displaced AXH N-terminal sequences together with the ability of the domain to recognize sequences with both direct and reversed backbone orientation strongly suggest that, as for the SH3 motif in proteins, this could thus be a more general mechanism to modulate the functions of ATX1. At variance with SH3 domains is, however, the plasticity of the backbone recognition: while having low sequence specificity, all SH3 complexes share a very similar backbone conformation. The AXH domain seems instead to be much more tolerant against both sequence and structural restraints according to its chameleon properties and to recognize the partner after remodelling of the binding surface.

Even more important are the implications of our findings for ATX1 self-association and therefore, potentially, for the SCA1 disease. We have previously demonstrated that the AXH dimer is on the pathway to the formation of tetramers and other higher

Figure 6. Model of the competition between protein-protein interactions and self-assembly determines the fate of the domain. In solution, the AXH monomer is in equilibrium with the dimer. In the presence of CIC, the equilibrium shifts towards the monomer that is drastically stabilized. In the absence of CIC or other cellular partners, AXH will be in a close state that is transcriptionally inactive. When this occurs, other modifiers such as polyQ expansion and/or any other perturbations will favour self-association of the domain.

doi:10.1371/journal.pone.0076456.g006
molecular weight species as the surface of dimerisation seems to involve elements from both protomers of the dimer [20]. This implies that interaction with CIC is in direct competition with AXH self-association (Figure 6), in agreement with the observation that transcriptional dysregulation occurs already at the very early stages of the disease [10,41,42]. The existence of a competition between normal and pathological functions is an important emerging concept observed also in other diseases. We previously demonstrated for ataxin-5, another member of the polyQ family, that aggregation is the ‘dark side’ of normal function [6,21]: the binding site of this protein for ubiquitin coincides with aggregation-prone hydrophobic surfaces that have evolved to allow partner recognition. While enforcing the concept and the importance of studying the non-pathological function of aggregation-prone proteins, our new results directly suggest a strategy for preventing AXH aggregation: it will be interesting to use the CIC peptide as a template to design peptide-mimetic molecules and to test whether and how much these lead compounds affect the overall ATX1 aggregation both by themselves and in combination with polyQ aggregation blockers. This route could be the first step towards the development of a specific strategy for the treatment of SCA1 and more in general of other polyQ diseases. Taken together, the ITC results suggest that an indole and an isobutyl group appropriately spaced from each other could mimic the W37 and L40 side-chains. They can be expected to be a strict starting requirement for the design of any molecule that can be recognised by the AXH domain and compete for interaction with CIC. Results from a thorough study of the structural-activity relationship based on the identification of disabled mutations of the peptide, and complemented by in cell assays, will pave the way to the design of potential inhibitors of such interaction. Fine tuning of the affinity of the mimetic molecule for AXH will be required in order to appropriately modulate its interaction with CIC without significantly interfering in vivo with other specific functional interactions mediated by the same AXH surface. More work is therefore needed to fully elucidate the cellular functions of the AXH domain and its exact role in aggregation and to explore the implications of these findings for therapy.

Materials and Methods

Protein Expression and Purification

Recombinant ATX1 AXH (residues A567–K689 of human ATX1) was over-expressed in the E.coli host strain BL21(DE3)-pLyS5 in Luria broth with Tobacco Etch Virus (TEV)-cleavable N-terminal His6-GST tag. Isotopically [15N] and [13C/15N] labelled samples were expressed in minimal (M9) medium supplemented with [15N]-ammonium sulphate and [13C]-glucose as the sole sources of nitrogen and carbon respectively. The cells were grown at 37° C until an optical density (OD) of 0.6 at 600 nm was reached, before inducing protein expression with IPTG (0.25 mM) for three hours followed by harvesting. A standard purification protocol was performed using a Ni-NTA agarose column (Qiagen). Protein identity was checked by ESI mass spectrometry.

Synthetic lyophilized CIC peptides (purity >95%) were purchased from Pepceuticals Limited (Nottingham-UK), dissolved in MilliQ water that was then exchanged with the final buffer using a PD MidiTrap G10 (GE Healthcare). AXH and CIC peptides concentrations were checked by measuring UV absorbance at 280 nm using a calculated extension coefficient of 8480 and 5500 M⁻¹cm⁻¹, respectively.

NMR Spectroscopy

NMR spectra for structural determination were acquired on samples containing [15N]- or [13C/15N]-labelled ATX1 AXH (0.5 mM) and unlabelled L-CICp (0.6 mM) (AXH:L-CICp molar ratio 1:1.2) in 20 mM Tris-HCl pH 6.85, 2 mM TCEP, 0.02% NaN₃, 8% 2H₂O. The spectra were recorded at 27°C using Varian Inova spectrometers operating at 600 and 800 MHz 1H frequency, the 800 MHz being equipped with a triple resonance gradient Cold-Probe, and Bruker Avance spectrometers operating at 600 and 700 MHz 1H frequency, both equipped with triple resonance gradient CryoProbes. Resonance assignment of the AXH/L-CICp complex was performed using a standard approach as previously described [26]. AXH intra-molecular proton distance restraints were derived from [15N] and [13C]-NOESY-HSQC spectra (mixing time 100 ms). Inter-molecular NOE restraints between double-labelled AXH and unlabelled L-CICp were obtained from 3D [15N,13C]-F1-filtered, [15N] and [13C]-edited NOESY spectra (mixing time 100 ms), whereas L-CICp intra-molecular NOEs from a 2D [15N,13C]-F1/F2-filtered NOESY (mixing time 100 ms) [43]. T₁ and T₂ and ³H-¹H-NOE measurements were performed at 27°C and 600 MHz by adapted standard pulse sequences. Rotational correlation times (τc) for the free and L-CICp-bound form were derived using a recently devised method (Kelly & Frenkiel, in preparation) which yields a rapid and direct estimate of the [15N] ¹H T₁/T₂ ratio from inspection of a series of 1D profiles.

Structure Determination

Automated NOESY cross-peak assignment and structure determination were performed by the ARIA 2.3 software [44] based on an almost complete assignment of the complex [26] and on a large number of intra- and inter-molecular NOEs. The ARIA input used to generate the final structures consisted of AXH intra-molecular NOE cross peaks from [15N] and [13C]-NOESY- HSQC spectra, L-CICp intra-molecular NOEs from 2D [15N,13C]-F1/F2-filtered NOESY and inter-molecular restraints from [15N,13C]- F1-filtered, [15N] and [13C]-edited NOESY along with a set of φ and ψ backbone dihedral restraints derived by TALOS+ [45]. Using this set of data the structure rapidly converged to a unique fold. In the final ARIA run, a number of 200 structures were generated in iteration 8. </p>
Analytical Size Exclusion Chromatography

Size exclusion chromatography was performed using a pre-packed Superdex-75™ 10/300 GL column (Pharmacia) equilibrated with a 20 mM Tris-HCl pH 7, 130 mM NaCl, 1 mM TCEP buffer solution. Aliquots of 250 µl of 200 µM AXH567-694 and AXH567-689 in the absence or presence of L-CICp, incubated in 20 mM Tris-HCl pH 7, 1 mM TCEP, at 37°C were injected and eluted using a 0.8 ml/min flow rate. Carbonic anhydrase (29 kDa), and ribonuclease A (13.7 kDa) were used as standards for the determination of the void volume of the column.

Analytical Size Exclusion Chromatography for Aggregation Experiments

Size exclusion chromatography was performed using a pre-packed Superdex-75™ 10/300 GL column (Pharmacia) equilibrated with a 20 mM Tris-HCl pH 7, 50 mM NaCl, 2 mM TCEP buffer solution. Samples of 150 µl of 0.2 mM ATX1 AXH, either free or in a 1:5 excess of L-CICp, were injected and eluted using a 0.8 ml/min flow rate. Carbonic anhydrase (29 kDa), and ribonuclease A (13.7 kDa) were used as standards for the molecular mass, whereas the Blue Dextran 2000 was used for the determination of the void volume of the column.

References

1. Orr HT, Chung MY, Banfi S, Kwiatkowski TJ Jr., Servadio A, et al. (1993) Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 4: 221–226.
2. Zoghbi HY, Orr HT (2009) Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J Biol Chem 284: 7425–7429.
3. Koeppen AH (2005) The pathogenesis of spinocerebellar ataxia. Cerebellum 4: 62–72.
4. Masino L (2004) Polyglutamine and neurodegeneration: structural aspects. Protein Pept Lett 11: 239–248.
5. de Chiara C, Menon RP, Dal Paz F, Calder L, Pastore A (2005) Polyglutamine is not all the functional role of the AXH domain in the ataxin-1 protein. J Mol Biol 354: 883–893.
6. Masino L, Nicastro G, Calder L, Vendruscolo M, Pastore A (2011) Functional interactions as a survival strategy against abnormal aggregation. FASEB J 25: 45–54.
7. Saunders HM, Bottomley SP (2009) Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins. Protein Eng Des Sel 22: 447–451.
8. Saunders HM, Gilis D, Roosman M, Dehouck Y, Robertson AL, et al. (2011) Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein. Protein Sci 20: 1675–1681.
9. Wang ZM, Lashuel HA (2013) Discovery of a novel aggregation domain in the huntingtin protein: implications for the mechanisms of Htt aggregation and toxicity. Angew Chem Int Ed Engl 52: 562–567.
10. Fernandez-Fuente P, Nino-Rosales ML, de Grooyer B, She WC, Luchak JM, et al. (2000) Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408: 101–106.
11. Tsuda H, Jalal-Nejad H, Patel AJ, Sun Y, Chen HK, et al. (2003) The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gli-1/Senseless proteins. Cell 122: 633–644.
12. Mushigian AR, Bassett DE Jr., Boguski MS, Bork P, Koonin EV (1997) Positionally cloned human disease genes: patterns of evolutionary conservation and functional motifs. Proc Natl Acad Sci USA 94: 5831–5836.
13. Mizutani A, Wang L, Rajan H, Vir JP, Aloy P, et al. (2005) Boa, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1. EMBO J 24: 3339–3351.
14. Lam YC, Bowman AB, Jalal-Nejad P, Lim J, Richman R, et al. (2006) ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127: 1335–1347.
15. Goold R, Hubank M, Hunt A, Holton J, Menon RP, et al. (2007) Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. Hum Mol Genet 16: 2122–2134.
16. Gehring KM, Andresen JM, Duvick L, Lough J, Zoghbi HY, et al. (2011) Partial loss of Trp60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model. Hum Mol Genet 20: 2204–2212.
17. Yue S, Serra HG, Zoghbi HY, Orr HT (2001) The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum Mol Genet 10: 25–30.
18. de Chiara C, Giannini C, Adinolfi S, de Boer J, Guida S, et al. (2003) The AXH module: an independently folded domain common to ataxin-1 and HBPI. FEBS Lett 531: 167–172.
19. Murzin AG (1993) OBolding nucleotide/diogasacharide-binding fold: common structural and functional solution for non-homologous sequences. Embo J 12: 861–867.
20. de Chiara C, Rees M, Menon RP, Pawels K, Lawrence C, et al. (2013) Self-assembly and conformational heterogeneity of the AXH domain of ataxin-1: an unusual example of a chameleonic fold. Biophys J 104: 1304–1313.
21. Pastore A, Temussi PA (2012) The two faces of Janus: functional interactions and protein aggregation. Curr Opin Struct Biol 22: 30–37.
22. Ehmhofer DE, Beschke J, Roedach A, Herbst M, Masino L, et al. (2008) EGCQ redirects amyloidiogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15: 558–566.
23. Lim J, Crespo-Barreto J, Jalal-Nejad P, Bowman AB, Richman R, et al. (2008) Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452: 713–718.
24. Kim E, Lu HC, Zoghbi HY, Song JJ (2013) Structural basis of protein complex formation and reconfiguration by polyglutamine disease protein Ataxin-1 and Capicua. Genes Dev 27: 500–513.
25. Fryer JD, Yu P, Kang H, Mandel-Brehm C, Carter AN, et al. (2011) Exercise and genetic rescue of SCA1 via the transcriptional repressor Capicua. Science 334: 690–693.
26. de Chiara C, Kelly G, Menon RP, McCormick J, Pastore A (2013) Chemical shift assignment of the ataxin-1 AXH domain in complex with a C1C ligand peptide. Biomol NMR Assign.
27. Chen YW, Allen MD, Veprintsev DB, Lowe J, Bycroft M (2004) The structure of the AXH domain of spinocerebellar ataxia-1. J Biol Chem 279: 3758–3765.
28. Thomas D, Pastore A (2003) WHEATSHAEF: an algorithm to average protein structure ensembles. Acta Crystallogr D Biol Crystallogr 61: 112–116.
29. de Chiara C, Menon RP, Adinolfi S, de Boer J, Kistaki E, et al. (2005) The AXH domain adopts alternative folding solutions the structure of HBPI AXH. Structure 13: 743–753.
30. Rain JC, Selig L, De Reuse H, Battaglia V, Reverdy C, et al. (2001) The protein-protein interaction map of Helicobacter pylori. Nature 409: 211–215.
31. Russell RB, Alfer F, Aloy P, Davis FP, Korkin D, et al. (2004) A structural perspective on protein-protein interactions. Curr Opin Struct Biol 14: 313–324.
32. Sardis ME, Washburn MP (2011) Building protein-protein interaction networks with proteomics and informatics tools. J Biol Chem 286: 23645–23651.
33. Andrevea A, Murzin AG (2006) Evolution of protein fold in the presence of functional constraints. Curr Opin Struct Biol 16: 399–408.
34. Burright EN, Davidson JD, Duvick LA, Koshy B, Zoghbi HY, et al. (1997) Identification of genes that modify ataxin-1-induced neurodegeneration. Nat Genet 4: 221–226.
35. Saunders HM, Gilis D, Rooman M, Dehouck Y, Robertson AL, et al. (2011) Identification of a self-association region within the SCA1 gene product, ataxin-1. Hum Mol Genet 20: 2122–2134.
36. Bolger TA, Zhao X, Cohen TJ, Tsai CC, Yao TP (2007) The neurodegenerative disease protein ataxin-1 antagonizes the neuronal survival function of myocyte enhancer factor-2. J Biol Chem 282: 29186–29192.
37. Tsai CC, Kao HY, Mitzutani A, Banayo E, Rajan H, et al. (2004) Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc Natl Acad Sci USA 101: 4047–4052.
38. Zen A, de Chiara C, Pastore A, Micheletti C (2009) Using dynamics-based comparisons to predict nucleic acid binding sites in proteins: an application to OB-fold domains. Bioinformatics 25: 1876–1883.
39. Irwin S, Vandelft M, Pinchev D, Howell JL, Graczyk J, et al. (2005) RNA association and nucleocytoplasmic shuttling by ataxin-1. J Cell Sci 118: 233–242.
40. de Chiara C, Menon RP, Strom M, Gibson TJ, Pastore A (2009) Phosphorylation of S776 and 14-3-3 binding modulate ataxin-1 interaction with splicing factors. PLoS One 4: e8372.
41. Lin X, Antalffy B, Kang D, Orz HT, Zoghbi HY (2000) Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci 3: 157–163.
42. Crespo-Barreto J, Fryer JD, Shave CA, Orr HT, Zoghbi HY (2010) Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genet 6: e1001021.
43. Otting G, Wuthrich K (1990) Heteronuclear filters in 2-Dimensional H-1, H-1 NMR-spectroscopy - combined use with isotope labeling for studies of macromolecular conformation and intermolecular interactions. Quarterly Reviews of Biophysics 23: 39–96.
44. Rieping W, Habeck M, Bardiaux B, Bernard A, Malliavin TE, et al. (2007) ARIA2: automated NOE assignment and data integration in NMR structure calculation. Bioinformatics 23: 301–302.
45. Shen Y, Delaglio F, Cornilescu G, Bax A (2009) TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. J Biomol NMR 44: 213–223.
46. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM (1996) AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 8: 477–498.
47. Ramachandran GN, Chandrasekaran R, Kopple KD (1971) Variation of the NH-C alpha-H coupling constant with dihedral angle in the NMR spectra of peptides. Biopolymers 10: 2113–2131.
48. Kawamura-Saito M, Yamazaki Y, Kaneko K, Kawaguchi N, Kanda H, et al. (2006) Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet 15: 2123–2137.